Semaglutide is a glucagon-like peptide-1 (GLP-1) drug, and is the active agent in Ozempic and its weight-loss cousin, Wegovy
Users report significant improvements in recovery capacity, skin quality, and body composition
revenue of $28B, with GLP-1s accounting for 80%, a 15% Medicare share, and a 50% price cut, the direct Medicare impact would equal roughly $1.7B , or 6% of U.S
That difference matters, especially during the critical early weeks when your body is adjusting and you are trying to find the right dose for microdosing protocols or standard escalation
Alongside liraglutide, semaglutide has been shown to effectively improve motor impairments, rescue tyrosine hydroxylase (TH) levels, reduce -synuclein accumulation, chronic inflammation response in the brain and lipid peroxidation, inhibit mitochondrial mitophagy signaling and protect dopaminergic neurons in the substantia nigra and striatum in MPTP mouse models of PD [81]